NPPA fixes price caps for 12 anti-diabetic medicines

Drug price regulator National Pharmaceutical Pricing Authority (NPPA) on Monday said it has fixed the ceiling prices for 12 anti-diabetic generic medicines, including glimepiride tablets, glucose injection and intermediate acting insulin solution. In a tweet, the drug price regulator said, “To make it possible for every Indian to afford medical treatment against diseases like diabetes, NPPA has initiated a successful step by fixing the ceiling prices of 12 anti-diabetic generic medicines.”

These include glimepiride tablet of strength 1 mg, with ceiling price at Rs 3.6 per tablet, while that for 2 mg is Rs 5.72 per tablet.

The ceiling price of 1 ml glucose injection of 25 per cent strength has been fixed at 17 paise, while that of 1ml of insulin (soluble) injection of strength 40IU/ml is Rs 15.09.

Similarly, 1 ml of intermediate acting (NPH) solution insulin injection of strength 40 IU/ml has a ceiling price of Rs 15.09, and that of 1 ml of premix insulin 30:70 injection (regular NPH) injection of strength 40 IU/ml is also Rs 15.09.

NPPA further said the ceiling price of metformin immediate release tablet of strength 500 mg has been fixed at Rs 1.51 per tablet, while that of 750 mg strength is at Rs 3.05 per tablet and 1,000 mg strength at Rs 3.61 per tablet.

For metformin control release tablet of strength 1000 mg, the ceiling price is Rs 3.66 per tablet, NPPA said, adding the same for 750 mg strength is Rs 2.4 per tablet and Rs 1.92 per tablet for metformin control release tablet of strength 500 mg.

  • Related Posts

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    Prices of nearly 900 essential medicines, including painkillers and antibiotics, are set to rise by around 0.65 per cent starting 1 April following a directive from India’s drug pricing regulator.…

    Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

    The court also asked Dr Reddy’s to inform it by Friday whether it is willing to drop the “Olymviq” brand name, as the matter centres around alleged trademark similarity with…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

    Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

    NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise

    NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise

    Govt Outlines AYUSH Heavy Metal Monitoring Steps In Rajya Sabha

    Govt Outlines AYUSH Heavy Metal Monitoring Steps In Rajya Sabha

    Regulation Of Hair Transplant And Cosmetic Clinics Under The Purview Of States, No Plans To Create A Central Database Or Registry: Govt In RS

    Regulation Of Hair Transplant And Cosmetic Clinics Under The Purview Of States, No Plans To Create A Central Database Or Registry: Govt In RS

    24-year-old woman dies during surgery; Five UP doctors booked for negligence

    24-year-old woman dies during surgery; Five UP doctors booked for negligence